AzTrials
AzTrials

Ventricular TachycardiaEPICONTAC-VTNCT01847378

Feasibility of Contact Force Catheter Mapping and Ablation in Epicardial and Endocardial Ventricular Tachycardias

An observational study of Ventricular Tachycardia and Sudden Death, run by Federal University of São Paulo at 3 sites in Brazil.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Ventricular tachycardia is one of the commonest cause of sudden death in chronic chagas disease. As most ventricular tachycardias originate from scar in patients with heart disease, catheter ablation is an important step in patient treatment. Read more about this study

Who is it for?
Ages 18 to 80 years
Conditions the study is for
Ventricular Tachycardia, Sudden Death, Syncope
What is being tested?
Catheter ablation
Type of treatment
Surgery or procedure
How many people
10 participants
Where
3 sitesBrazil
Study dates
Jun 2013to Aug 2015
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Chagasic patients with symptomatic documented ventricular tachycardia

Who may be able to join

  • individuals aged between 18 and 80 years old
  • life expectancy greater than 1 year
  • positive reaction in at least two different serologic techniques for Chagas disease (ELISA, indirect hemagglutination or indirect immunofluorescence)
  • symptomatic recurrent monomorphic ventricular tachycardia (recorded by holter, electrocardiogram or looper)
  • prior to implantable cardioverter defibrillator implantation in patients with ventricular tachycardia as an attempt to prevent shoks
  • patients in "electrical storm", defined as three or more episodes of ventricular tachycardia in 24h. Each episode must demand a medical intervention.
  • monomorphic ventricular tachycardia induced during electrical physiological study in patients with syncope of unexplained cause

Who cannot join

  • claustrophobia
  • creatinine clearance inferior to 30ml/min/m2 (clearance between 30ml/min/m2 and 60ml/min/m2 will be analyzed individually)
  • thrombus in the left ventricle
  • pregnancy
  • heart failure NYHA IV
  • allergy to iodinated contrast or gadolinium
Show all 9Show fewer
  • patients with implantable devices (pacemakers, implantable defibrillators and similar)
  • coagulopathy (INR > 1,5 or aPTT 2x normal values)
  • platelet count inferior to 100.000

Trial locations and contacts

3 sites in 1 country.

Enia L Coutinho, Coordinator contact

+55(11)992914070

coutinho.enia@gmail.com

Brazil3 sites, 3 recruiting
  • Federal University of São Paulo, São Paulo Hospital

    São Paulo, São Paulo, 04024-002

    Enia L Coutinho, coordinator, +55(11)992914070, coutinho.enia@gmail.com

    Lucas H Oliveira, MD

    Recruiting
  • Federal University of São Paulo

    São Paulo, São Paulo, 04024-002

    Lucas H Oliveira, MD, Msc, +55(11)99975-0937, lucas.hollanda@unifesp.br

    Angelo AV de Paola, MD, pHD

    Recruiting
  • Federal University of São Paulo

    São Paulo, São Paulo, SP

    Enia L Coutinho, Coordinator, +55(11)992914070, coutinho.enia@gmail.com

    Lucas H Oliveira, MD

    Not yet recruiting

Other trials in Brazil

About this study

Official title: EPIcardial and Endocardial Mapping and Ablation Using Contact Force Catheter in Chagasic Patients With Sustained Ventricular Tachycardia

Ventricular tachycardia is one of the commonest cause of sudden death in chronic chagas disease. As most ventricular tachycardias originate from scar in patients with heart disease, catheter ablation is an important step in patient treatment. Identification of fibrosis prior to ablation of sustained ventricular tachycardia (SVT) might reduce the time of anesthesia, procedure time, radiation exposure and possibly the risk of complications. Knowledge of arrhythmia circuit within scar allows planning strategies for each procedure. Condreanu et al. stablished that voltages inferior to 6.52 mV (unipolar) and 1.54mV (bipolar) are useful tools in detecting scar during electroanatomic mapping. Accuracy, however when compared to magnetic resonance imaging is limited due to difficulties in maintaining good contact between ablation catheter and ventricular wall. Contact force catheters might help increase accuracy of voltage mapping because they allow detection of poor contact areas. Although the threshold for identification of scar in ischemic and non ischemic patients during electroanatomical mapping is already known, this parameters still lacking for chronic chagasic individuals. A marked qualitative histological difference between these fibrous scars supports the hypothesis that voltage scar in chagasics might be different. Catheter ablation contact with endo and epicardial surface is an important issue when ablating arrhythmias. Conventional catheter ablation is not equipped with sensors capable of detecting degree of contact with the target. To our knowledge, the literature lacks information in regard to late lesions produced by a known contact force pressure "in vivo". The pattern of electrical activation in these patients and their relationship with local coronary veins for resynchronization likely to approach through the coronary sinus can be useful in defining chagasic that can benefit from resynchronization.

  1. Compare endocardial and epicardial impedance and voltage using CARTO 3 with fibrosis on 3T MRI
  2. Correlate areas of late activation within scar during activating mapping in sinus rhythm with different signal intensity in 3T MRI
  3. Evaluate the influence of contact pressure during application of radiofrequency in making fibrosis analyzed 30 days after the procedure using a 3T MRI.
  4. Assess the site of latest left ventricular activation in sinus rhythm and correlate with the coronary veins location
Being tested
Catheter ablation
Keywords
ventricular tachycardia, catheter ablation, chagas disease, epicardial mapping, magnetic resonance imaging
Medical subject headings
Tachycardia, Ventricular, Death, Sudden, Syncope, Chest Pain, Chagas Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Catheter ablationProcedure or surgery

    During mapping and ablation tissue voltage and impedance will be stored and analyzed thereafter. The same procedure will be done in regard to activating maps.

Study groups in NCT01847378
Study groupRoleWhat they receive
Catheter ablationPatients with chronic chagasic disease and documented monomorphic ventricular tachycardia
Receives: Procedure: Catheter ablation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Evaluate the feasibility of mapping and ablating ventricular tachycardias in endocardial and epicardial using a contact force catheter

    The feasibility will be evaluated immediatly after the procedure

    Measured: Immediatly after the procedure

Secondary outcomes (1)
  1. Evaluate the impedance and voltage threshold for scar in chronic chagasic cardiomyopathy

    Measured: After the procedure

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 May 2013 (estimated)
  2. Study startJun 2013
  3. Primary completionMay 2015 (estimated)
  4. Study completionAug 2015 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
10 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01847378
Sponsor's protocol ID
ISII
Acronym
EPICONTAC-VT
Status last verified
Oct 2014
First submitted
2 May 2013
Last updated
21 Oct 2014
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

An observational study of Ventricular Tachycardia and Sudden Death, run by Federal University of São Paulo at 3 sites in Brazil.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 21 Oct 2014. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Lucas H Oliveira, MD (+55(11)99750937 ext. 55, lucas.hollanda@unifesp.br), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Evaluate the feasibility of mapping and ablating ventricular tachycardias in endocardial and epicardial using a contact force catheter (time frame: Immediatly after the procedure). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Oct 2014.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in